Effects of altered 5-ht6 expression in the rat: functional studies using antisense oligonucleotides

doi:10.1016/0166-4328(96)00105-2

Behavioural Brain Research

Volume 73, Issues 1–2, 15 December 1995, Pages 245-248

https://doi.org/10.1016/0166-4328(96)00105-2 Get rights and content

Abstract

The purpose of the present study was to determine whether the 5-ht₆ receptor is functionally expressed in the rat brain by blocking its translation from mRNA with treatments of phosphorothioate antisense oligonucleotides. Rats were treated with either saline, antisense (AO) or scrambled oligonucleotides (SO) for 4 days. Treatment with AO reduced the number of [³H]LSD binding sites in the frontal lobes by 30% but had no significant effect on the number of 5-HT_1A and 5-HT_2A receptor binding sites in the cortex of the rats. A behavioural syndrome of yawning, stretching and chewing, however, was observed in AO treated rats but not in any of the other treatment groups. This AO-specific behaviour had returned to normal 5 days after cessation of the oligodeoxynucleotide treatment. These data suggest that the 5-ht₆ receptor has a physiological function in the rat brain where it appears to be under the tonic control of endogenous 5-HT.

References (12)

P.P.A. Humphrey et al.
A proposed new nomenclature for 5-HT receptors
TIPS
(1993)
L.M. Liau et al.
Characterisation of a novel and potent 5-hydroxytryptamine_1A recept or antagonist
Pharmacol. Biochem. Behav.
(1991)
Y. Shen et al.
Molecular cloning and expression of a 5-hydroxytryptamine₇ serotonin receptor subtype
J. Biochem. Chem.
(1993)
A. Argiolas et al.
Yawning and penile erection: Central dopamine-oxytocin-adrenocorticotrophin connection
Ann. NY Acad. Sci.
(1988)
B. Holmgren et al.
Interaction of cholinergic and dopaminergic influences on yawning behaviour
Acta Neurobiol.
(1980)
H. Matthes et al.
Mouse 5-hydroxytryptamine_5A and 5-dydroxytryptamine_5B receptors define a new family of serotonin receptors: Cloning functional expression and chromosomal localisation
Mol. Pharmacol.
(1993)

There are more references available in the full text version of this article.

Cited by (52)

The application of the Fischer indole synthesis in medicinal chemistry
2023, Advances in Heterocyclic Chemistry
The indole ring system is an important scaffold in a great number of biologically significant molecules and hence there are numerous methods to access this heterocyclic ring system. The Fischer indole reaction is one of the oldest methods, and due to its versatility, it is a widely employed method of preparing substituted indoles. This review will cover the period from 2016 to June 2022 and will focus on the application of the method in the area of medicinal chemistry.
Antagonism of the 5-HT<inf>6</inf> receptor – Preclinical rationale for the treatment of Alzheimer's disease
2017, Neuropharmacology
Citation Excerpt :
An interesting question is whether the presence of an AChEI is merely a means to raise extracellular ACh to detectable levels or whether the enhanced cholinergic tone is a prerequisite for the 5-HT6 receptor antagonist to be efficacious (synergistic mechanism). The original studies with antisense oligonucleotides suggest that knockdown of the 5-HT6 receptor is, in and of itself, sufficient to increase ACh levels (Bourson et al., 1995; Sleight et al., 1996). The effects observed with small molecule receptor antagonists are more modest and may be amplified in the presence of an AChEI that reduces clearance of ACh from the extracellular space (Dawson, 2011; Herrik et al., 2016).
Antagonism of the 5-HT₆ receptor is a promising approach for the symptomatic treatment of Alzheimer's disease (AD). There is compelling preclinical evidence for the procognitive potential of 5-HT₆ receptor antagonists and several compounds are in clinical development, as adjunct therapy to acetylcholinesterase inhibitors (AChEIs). This manuscript summarizes the scientific rationale for the use of 5-HT₆ receptor antagonists as AD treatment, with some focus on the selective and high-affinity 5-HT₆ receptor antagonist idalopirdine (Lu AE58054).
The 5-HT₆ receptor is enriched in brain regions that mediate cognition, where expression predominates on glutamatergic and GABAergic neurons and subsets of GABAergic interneurons. It is proposed that 5-HT₆ receptor antagonism modulates the balance between neuronal excitation (glutamate) and inhibition (GABA), which may have widespread implications for neurotransmission and neuronal activity. This is supported by preclinical studies showing that 5-HT₆ receptor antagonists increase concentrations of multiple neurotransmitters, and strengthened by recent evidence that idalopirdine facilitates neuronal oscillations and contributes to the recruitment of several neuronal networks relevant in cognition. Some of these effects are observed with idalopirdine monotherapy, whereas others require concomitant treatment with an AChEI. Several hypotheses for the mechanism underlying the synergistic actions between 5-HT₆ receptor antagonists and AChEIs are discussed. Collectively, the current evidence suggests that 5-HT₆ receptor antagonism adds a unique, complementary mechanism of action to that of AChEIs. The facilitation of multiple neurotransmitters and neuronal activity in brain regions that mediate cognition, and the synergy with AChEIs, are proposed to mediate the procognitive effects of 5-HT₆ receptor antagonists in AD patients.
6-Sulfonylbenzothiazolones as potential scaffolds for the design of 5-HT<inf>6</inf> ligands
2015, European Journal of Medicinal Chemistry
5-HT₆ Receptors are relatively recently discovered receptors that interact with cholinergic, glutamatergic, GABAergic and dopaminergic transmission systems. These receptors have been implicated in the CNS system as therapeutic targets in applications such as psychosis, reduction of body weight or Alzheimer's disease. As part of our efforts to develop 5-HT₆ antagonists, we explored the benzothiazolone scaffold substituted in position 3 or 6 respectively with ethylamino chains and an aromatic ring connected through a sulfonyl linker. Final compounds were evaluated in radioligand binding assays for their ability to interact with 5-HT₆ receptors. Their potential cytotoxic effects were determined on the human neuroblastoma cell line SY5Y. They showed very low cytotoxicity, and one of them has submicromolar affinity for 5-HT₆ receptors.
Structure activity relationship studies of 3-arylsulfonyl-pyrido[1,2-a] pyrimidin-4-imines as potent 5-HT<inf>6</inf> antagonists
2014, Bioorganic and Medicinal Chemistry
Citation Excerpt :
In individuals afflicted with Alzheimer’s disease (AD), the loss of cognitive function correlates with a decrease in cholinergic neurotransmission. Disruption of 5-HT6 receptor expression, or blockade of 5-HT6 receptor signaling, increases regional cholinergic tone and produces a behavioral syndrome that is reversed by centrally-acting muscarinic antagonists, suggesting that the 5-HT6 receptor is involved in the negative regulation of acetylcholine-mediated neurotransmission.4–6 Correspondingly, it is anticipated that 5-HT6 receptor antagonists may improve cognitive function in patients with AD and schizophrenia.7–11
Comprehensive structure activity relationship (SAR) studies were conducted on a focused screening hit, 2-(methylthio)-3-(phenylsulfonyl)-4H-pyrido[1,2-a]pyrimidin-4-imine (1, IC₅₀: 4.0 nM), as 5-HT₆ selective antagonists. Activity was improved some 2–4 fold when small, electron-donating groups were added to the central core as observed in 19, 20 and 26. Molecular docking of key compounds in a homology model of the human 5-HT₆ receptor was used to rationalize our structure–activity relationship (SAR) findings. In pharmacokinetic experiments, compound 1 displayed good brain uptake in rats following intra-peritoneal administration, but limited oral bioavailability.
1-(Arylsulfonyl)-2,3-dihydro-1H-quinolin-4-one derivatives as 5-HT <inf>6</inf> serotonin receptor ligands
2011, Bioorganic and Medicinal Chemistry Letters
Behavioral and Neurochemical Pharmacology of 5-HT6 Receptors Related to Reward and Reinforcement
2011, International Review of Neurobiology
This chapter provides an overview of the neurochemical and behavioral pharmacology of 5-HT₆ receptors rather than the one strictly confined to their role in motivation, reward, and extrapyramidal functions. In spite of their high density in the striatum and, particularly in the ventral striatum, endogenous 5-HT₆ receptors do not appear to affect behaviors classically related to the ventral striatum, such as motivation and reward, by a direct action in this area. Rather, the involvement of endogenous 5-HT₆ receptors in these functions seems to take place indirectly via their influence on dopamine (DA) transmission. Thus, some, but not all, agonists of 5-HT₆ receptors increase extracellular DA; and depending on the agonist, different transduction pathways and different behavioral effects can be elicited. These differences in the behavioral effects of 5-HT₆ receptor agonists may be related to the fact that different agonists induce different conformations in the 5-HT₆ receptor with differential affinity for different transduction pathways.

View all citing articles on Scopus

View full text

Effects of altered 5-ht6 expression in the rat: functional studies using antisense oligonucleotides

Abstract

TIPS

Pharmacol. Biochem. Behav.

J. Biochem. Chem.

Yawning and penile erection: Central dopamine-oxytocin-adrenocorticotrophin connection

Ann. NY Acad. Sci.

Interaction of cholinergic and dopaminergic influences on yawning behaviour

Acta Neurobiol.

Mouse 5-hydroxytryptamine5A and 5-dydroxytryptamine5B receptors define a new family of serotonin receptors: Cloning functional expression and chromosomal localisation

Mol. Pharmacol.

Effects of altered 5-ht₆ expression in the rat: functional studies using antisense oligonucleotides

Mouse 5-hydroxytryptamine_5A and 5-dydroxytryptamine_5B receptors define a new family of serotonin receptors: Cloning functional expression and chromosomal localisation